The Potential for Genome Editing Technology to Transform Medicine

Nessan Bermingham, Intellia Therapeutics

The Potential for Genome Editing Technology to Transform Medicine

Nessan Bermingham, Chief Executive Officer, President and Founder, Intellia Therapeutics

Nessan Bermingham is the entrepreneur and life sciences investor whose vision and drive made Intellia “one of the top 10 biotech start-ups in 2014,” according to Nature Biotechnology. Nessan has more than 15 years of experience investing in life sciences through venture, public, and secondary markets, focusing on technologies including small molecules, biologics, medical devices, and diagnostics. As a partner at Atlas Venture and Omega Funds, and founding partner of Bio Equity Capital, he successfully managed multiple investments across the United States and Europe. Nessan has cofounded a number of health-care and biotech startups and was previously the CEO of Tal Medical, a medical device company spun out of Harvard Medical School. Most recently, he was a venture partner at Atlas Venture, and he currently serves on Intellia’s board of directors. He received his PhD in molecular biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine.

Topics

Rewriting Life
Reprogramming our bodies to make us healthier.

Please enter your email address to view this free video.

We'd like to keep in touch about future MIT Technology Review initiatives and events.